Rajesh Kumar (HSBC) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Rajesh Kumar's stock ratings?

About 58% of Rajesh's ratings were profitable over a one-year hold, with an average return of +11.5% per rating, measured by 13Foresight from historical prices.

Q: How is Rajesh ranked?

Rajesh Kumar is ranked #1108 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Rajesh Kumar

HSBC

Rajesh Kumar

HSBC

Wall Street Analyst

★★★☆☆

#1108

on 13Foresight · ranked by our own returns

62%

Success Rate

+12.1%

Average Return

15 of 24 calls profitable · -7.8% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 62% of Rajesh Kumar's ratings turned a profit when each position was held for 2 year — averaging +12.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

27 Buy 17 Hold 5 Sell

Rajesh's Stock Coverage 48 ratings · 2026-07-13

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	2-Yr Return
CVS CVS Health	Jul 06, 2026	HOLD	Strong Buy -1.6% avg upside 39 analysts	$103.00 1.16% Downside	+2.0%
CH:LONN Lonza Group Ltd	Jul 06, 2026	BUY	Strong Buy +9.8% avg upside 20 analysts	$640.00 9.37% Upside	·
CH:ROP Roche Holding AG	Jul 06, 2026	HOLD	Buy -1.1% avg upside 23 analysts	$365.00 8.31% Upside	·
GB:0QIU Novo Nordisk	Jul 06, 2026	HOLD	Buy +27.3% avg upside 29 analysts	$300.00 6.62% Downside	·
GB:GSK GlaxoSmithKline	Jul 06, 2026	HOLD	Hold -3.2% avg upside 25 analysts	$1860.00 5.15% Downside	·
GB:AZN AstraZeneca	Jul 06, 2026	BUY	Strong Buy +17.0% avg upside 26 analysts	$16500.00 29.68% Upside	·
ABBV AbbVie	Jul 06, 2026	BUY	Strong Buy -6.7% avg upside 46 analysts	$300.00 20.91% Upside	-2.6%
REGN Regeneron	Jul 06, 2026	BUY	Strong Buy +16.1% avg upside 58 analysts	$800.00 20.43% Upside	+2.3%
PFE Pfizer	Jul 06, 2026	HOLD	Buy +39.1% avg upside 45 analysts	$28.00 15.93% Upside	+1.9%
MRK Merck & Company	Jul 06, 2026	BUY	Strong Buy +4.2% avg upside 43 analysts	$150.00 21.51% Upside	-2.6%
FR:DIM Sartorius Stedim Biotech	Jun 03, 2026	BUY	Strong Buy +35.9% avg upside 11 analysts	$230.00 25.30% Upside	·
LLY Eli Lilly & Co	Mar 17, 2026	SELL	Strong Buy -13.5% avg upside 47 analysts	$850.00 28.56% Downside	-28.0%
CH:NOVN Novartis AG	Mar 17, 2026	SELL	Buy -13.7% avg upside 31 analysts	$95.00 23.70% Downside	·
BMY Bristol-Myers Squibb	Mar 17, 2026	HOLD	Buy +2.3% avg upside 42 analysts	$60.00 4.17% Upside	-1.5%
NVO Novo Nordisk	Dec 10, 2025	HOLD	Buy +134.3% avg upside 26 analysts	$54.00 9.21% Upside	+4.6%
FR:SAN Sanofi	Dec 10, 2025	BUY	Strong Buy +28.9% avg upside 30 analysts	$100.00 29.34% Upside	·
DE:BAYN Bayer	Dec 10, 2025	BUY	Strong Buy +3.9% avg upside 28 analysts	$40.00 20.45% Downside	·
RHHBY Roche Holding	Dec 10, 2025	BUY	Buy -3.9% avg upside 14 analysts	$57.00 9.91% Upside	+5.2%
NVS Novartis	Dec 10, 2025	SELL	Buy -11.8% avg upside 24 analysts	$112.00 27.29% Downside	-21.0%
SNY Sanofi	Dec 02, 2025	BUY	Strong Buy +68.9% avg upside 20 analysts	$113.97 161.97% Upside	-7.0%
ROG Rogers	Dec 02, 2025	BUY	Strong Buy +102.2% avg upside 6 analysts	$450.57 227.56% Upside	+59.1%
TEVA Teva Pharmaceutical	Apr 28, 2025	BUY	Buy -10.8% avg upside 39 analysts	$20.00 39.36% Downside	+119.4%
GB:0MGB Genmab A/S	Apr 28, 2025	BUY	Buy +14.7% avg upside 22 analysts	$1990.00 5.23% Upside	·
GB:0NZT UCB SA	Apr 28, 2025	BUY	Buy -8.3% avg upside 19 analysts	$179.00 27.19% Downside	·
GILD Gilead Sciences	Dec 04, 2024	HOLD	Strong Buy -8.2% avg upside 66 analysts	$82.00 36.85% Downside	+48.7%
IQV IQVIA Holdings	Dec 04, 2024	BUY	Strong Buy +8.5% avg upside 38 analysts	$270.00 29.84% Upside	+2.9%
TMO Thermo Fisher	Apr 30, 2024	BUY	Strong Buy +11.5% avg upside 38 analysts	$670.00 27.17% Upside	-15.2%
DHR Danaher	Apr 16, 2024	BUY	Strong Buy +8.5% avg upside 45 analysts	$280.00 40.61% Upside	-18.4%
MRNA Moderna	Feb 26, 2024	SELL	Hold +1.7% avg upside 38 analysts	$86.00 25.92% Upside	+45.0%
FERG Ferguson PLC	Feb 14, 2024	BUY	Strong Buy +62.7% avg upside 35 analysts	$236.38 4.00% Upside	+39.6%
DE:MRK Merck KGaA	Dec 18, 2023	BUY	Buy -2.6% avg upside 33 analysts	$170.00 22.53% Upside	·
BNTX BioNTech SE	Oct 16, 2023	HOLD	Strong Buy +49.1% avg upside 26 analysts	$111.00 21.32% Upside	+8.4%
SE:SOBI Swedish Orphan Biovitrum AB	Sep 01, 2023	BUY	Strong Buy -13.5% avg upside 7 analysts	$260.00 44.05% Downside	·
GB:CTEC ConvaTec	Mar 22, 2023	SELL	Strong Buy +36.5% avg upside 17 analysts	$200.00 6.36% Downside	·
DE:FME Fresenius Medical Care AG & Co. KGaA	Mar 07, 2023	SELL	Buy +21.3% avg upside 22 analysts	$33.00 22.17% Downside	·
GB:DCC DCC plc	Dec 09, 2022	BUY	Strong Buy +0.0% avg upside 10 analysts	$6565.00 3.95% Upside	·
GB:BNZL Bunzl plc	Oct 20, 2022	HOLD	Buy +0.9% avg upside 16 analysts	$2880.00 7.17% Upside	·
CH:SGSN SGS SA	Apr 08, 2022	HOLD	Buy +1133.4% avg upside 26 analysts	$2860.00 2922.57% Upside	·
FR:ERF Eurofins Scientific	Apr 08, 2022	HOLD	Buy +44.1% avg upside 17 analysts	$92.00 32.60% Upside	·
FR:BVI Bureau Veritas	Apr 08, 2022	BUY	Buy +7.1% avg upside 25 analysts	$31.00 14.15% Upside	·
GB:ITRK Intertek	Apr 08, 2022	HOLD	Hold +796.4% avg upside 23 analysts	$5700.00 1.93% Downside	·
GB:INF Informa	Jan 26, 2022	BUY	Strong Buy +532.7% avg upside 18 analysts	$685.00 23.44% Downside	·
DE:BNR Brenntag AG	Sep 28, 2021	BUY	Buy +21.0% avg upside 25 analysts	$96.00 68.82% Upside	·
NL:IMCD IMCD N.V.	Sep 28, 2021	BUY	Buy +50.6% avg upside 16 analysts	$195.00 128.97% Upside	·
GB:EXPN Experian	Mar 19, 2021	BUY	Strong Buy +271.0% avg upside 19 analysts	$3200.00 23.20% Upside	·
GB:RS1 RS Group PLC	Jan 13, 2021	BUY	Strong Buy +23.2% avg upside 10 analysts	$1000.00 61.23% Upside	·
EXPGY Experian	May 06, 2020	BUY	Buy +5.8% avg upside 8 analysts	—	+8.9%
GB:DPLM Diploma	Apr 06, 2020	HOLD	Strong Buy -19.4% avg upside 8 analysts	$1370.00 79.71% Downside	·

🔒 43 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Rajesh Kumar — Frequently Asked Questions

How accurate are Rajesh Kumar's stock ratings?

Based on the calls 13Foresight could measure, about 58% of Rajesh's ratings were profitable over a one-year hold, with an average return of +11.5% per rating, or -1.9% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Rajesh ranked on 13Foresight?

Rajesh Kumar is currently ranked #1108 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Rajesh cover?

Rajesh most recently has ratings on CVS, CH:LONN, CH:ROP, GB:0QIU, GB:GSK, GB:AZN, ABBV, REGN, PFE, MRK, FR:DIM, LLY and 36 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!